Correspondence on "involuntary movements during vitamin b12 treatmentg": Was cyanocobalamin perhaps responsible?

Journal of Child Neurology

Volumn 25, Issue 6, 2010, Pages 794-795

  Gräbeck, Ralph ^a  

^a MINERVA FOUNDATION INSTITUTE FOR MEDICAL RESEARCH   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

COBALAMIN; CYANOCOBALAMIN; HYDROXOCOBALAMIN;

AMBLYOPIA; CYANOCOBALAMIN DEFICIENCY; DRUG EFFECT; DRUG USE; DYSKINESIA; HUMAN; LETTER; MYALGIA; NEUROLOGIC DISEASE; NONHUMAN; PERNICIOUS ANEMIA; PRIORITY JOURNAL; SCHILLING TEST;

DYSKINESIA, DRUG-INDUCED; HUMANS; VITAMIN B 12;

EID: 77952912818     PISSN: 08830738     EISSN: 17088283     Source Type: Journal    
DOI: 10.1177/0883073810369834     Document Type: Letter

References (7)

1. Özdemir Ö., Baytan B., Gunes AM, Okan M. Involuntary movements during vitamin B12 treatment. J Child Neurol. 2010 ; 25: 227-230.
2. Kim J., Gherasim C., Banerjee R. Decyanation of vitamin B12 by a trafficking chaperone. Proc Natl Acad Sci USA. 2008 ; 105: 14551-14554.
3. Begley JA, Horch C., Hall CA Preparation of labelled (57Co) sulfitocobalamin. Preparat Biochem. 1978 ; 8: 411-419.
4. Foulds WS, Freeman AG, Phillips CI, Wilson J. Cyanocobalamin: a case for withdrawal. Lancet. 1970 ; i (1). 35.
5. Arnstein HRV, Wrighton RJ The Cobalamins: A Glaxo Symposium. Edinburgh, UK: Churchill Livingstone; 1971.
6. Gräbeck R. Imerslund-Gräbeck syndrome (selective vitamin B12 malabsorption with proteinuria). Orphanet J Rare Dis. 2006 ; 1: 17.
7. Gräbeck R., Sarparanta M. Preparation and biodistribution of 32P-labelled hydroxocobalamin and comparison with 57Cocobinamide and cyanocobalamin. J Label Compd Radiopharm. 2008 ; 51: 59-63.